Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET
Company Participants
Dan Passeri - Chief Executive Officer
Anish Suri - President & Chief Scientific Officer
Matteo Levisetti - Chief Medical Officer
Kerri Millar - Chief Financial Officer
Conference Call Participants
Ted Tenthoff - Piper Sandler
Ren Benjamin - JMP Securities
Operator
Greetings, and welcome to the Cue Biopharma Investor Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the presentation. [Operator Instructions] As a reminder, this conference is being recorded.
I would now like to turn the conference over to Dan Passeri, Cue Biopharma’s Chief Executive Officer. Thank you. You may begin.
Dan Passeri
Hi. Thank you very much, and good afternoon, everyone. As a reminder, this presentation and discussions being recorded and will be available on our website for the next 30 days. Also please be aware that the slide accompanying today’s update maybe advance directly by those listening in on the call, and we'll notifying you as we proceed through the presentation.
Joining me on today's call is Dr. Anish Suri, our President and Chief Scientific Officer; Dr. Matteo Levisetti, our Chief Medical Officer; and Kerri Millar, our Chief Financial Officer.
As shown on slide number 2, this presentation and overview may contain some forward-looking statements, and any forward-looking statements made during this call represents the company's views as of today, August 09, 2023.
On the next slide, which is slide number 3, it just outlines the agenda for today's call, and I'll begin with a brief summary followed by Anish. Anish will provide you with some background context pertaining to our approach and result in developments regarding the Immuno-STAT platform with a brief synopsis of associated competitive advantages pertaining to the observations from our ongoing clinical trials.
Following the background provided by Anish, Matteo will then provide an update on observations from our ongoing clinical development regarding mechanistic insights, having corporate development implications for our ongoing corporate strategic positioning.
Both Anish and Matteo, during the presentation, we'll be providing updates with some of the data and slides having been previously presented and discussed on prior calls. The repeat of that data is meant to provide context and continuity in our foundational premise, but also serves to reinforce the consistent and steady progress forward, demonstrating the realization of our foundational vision to enable precision immunotherapy helping to transform the treatment of cancer.